MA47167A - Composés pyrazolopyrimidine et leurs procédés d'utilisation - Google Patents

Composés pyrazolopyrimidine et leurs procédés d'utilisation

Info

Publication number
MA47167A
MA47167A MA047167A MA47167A MA47167A MA 47167 A MA47167 A MA 47167A MA 047167 A MA047167 A MA 047167A MA 47167 A MA47167 A MA 47167A MA 47167 A MA47167 A MA 47167A
Authority
MA
Morocco
Prior art keywords
methods
pyrazolopyrimidine compounds
pyrazolopyrimidine
compounds
Prior art date
Application number
MA047167A
Other languages
English (en)
Inventor
Limin Cheng
Yun-Xing Cheng
Paul Gibbons
Wei Li
F Anthony Romero
Po-Wai Yuen
Mark Zak
Guiling Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA47167A publication Critical patent/MA47167A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA047167A 2016-12-29 2017-12-22 Composés pyrazolopyrimidine et leurs procédés d'utilisation MA47167A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016112932 2016-12-29

Publications (1)

Publication Number Publication Date
MA47167A true MA47167A (fr) 2019-11-06

Family

ID=61094385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047167A MA47167A (fr) 2016-12-29 2017-12-22 Composés pyrazolopyrimidine et leurs procédés d'utilisation

Country Status (19)

Country Link
US (1) US11155557B2 (fr)
EP (1) EP3562809B1 (fr)
JP (1) JP6900491B2 (fr)
KR (1) KR20190100337A (fr)
CN (1) CN110114343B (fr)
AU (1) AU2017385543A1 (fr)
BR (1) BR112019013287A2 (fr)
CA (1) CA3046435A1 (fr)
CL (1) CL2019001694A1 (fr)
CO (1) CO2019006220A2 (fr)
CR (1) CR20190310A (fr)
IL (1) IL267671A (fr)
MA (1) MA47167A (fr)
MX (1) MX2019007339A (fr)
PE (1) PE20191236A1 (fr)
PH (1) PH12019501022A1 (fr)
RU (1) RU2019123319A (fr)
UA (1) UA122851C2 (fr)
WO (1) WO2018122212A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017385543A1 (en) 2016-12-29 2019-05-23 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
WO2018215389A1 (fr) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Composés thérapeutiques, compositions et procédés d'utilisation associés
JP7339263B2 (ja) * 2018-01-15 2023-09-05 エフ． ホフマン－ラ ロシュ アーゲー Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
EP3986899A1 (fr) * 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Inhibiteurs éther-aryl-pyrazolopyrimidine de kinases jak et leurs utilisations
MX2021015319A (es) 2019-06-18 2022-04-07 Hoffmann La Roche Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.
US20200399274A1 (en) * 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2022175829A1 (fr) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Formulations et compositions topiques
EP4583977A1 (fr) * 2022-09-09 2025-07-16 Chiesi Farmaceutici S.p.A. Dérivés hétérocycliques comme inhibiteurs de janus kinase
IL319348A (en) * 2022-09-09 2025-05-01 Chiesi Farm Spa History of heterocyclics as Janus kinase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP0842195A1 (fr) 1995-07-06 1998-05-20 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
CA2470813A1 (fr) 2001-12-20 2003-07-03 Bayer Healthcare Ag Derives de 1,4-dihydro-1,4-diphenylpyridine
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
KR20110033223A (ko) 2008-06-20 2011-03-30 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EA032488B1 (ru) * 2014-05-23 2019-06-28 Ф. Хоффманн-Ля Рош Аг Соединения 5-хлор-дифторметоксифенилпиразолопиримидина, представляющие собой ингибиторы янус-киназы
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
JP6936236B2 (ja) 2016-02-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療化合物、組成物及びその方法の使用
SG11201811697SA (en) 2016-06-29 2019-01-30 Hanmi Pharmaceutical Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
AU2017385543A1 (en) 2016-12-29 2019-05-23 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof

Also Published As

Publication number Publication date
CL2019001694A1 (es) 2019-11-22
KR20190100337A (ko) 2019-08-28
BR112019013287A2 (pt) 2019-12-24
US11155557B2 (en) 2021-10-26
RU2019123319A (ru) 2021-02-01
PE20191236A1 (es) 2019-09-11
WO2018122212A1 (fr) 2018-07-05
AU2017385543A1 (en) 2019-05-23
CR20190310A (es) 2019-08-21
CA3046435A1 (fr) 2018-07-05
CN110114343A (zh) 2019-08-09
UA122851C2 (uk) 2021-01-06
CN110114343B (zh) 2022-09-06
CO2019006220A2 (es) 2019-06-28
EP3562809A1 (fr) 2019-11-06
JP6900491B2 (ja) 2021-07-07
RU2019123319A3 (fr) 2021-02-01
JP2020503339A (ja) 2020-01-30
IL267671A (en) 2019-08-29
PH12019501022A1 (en) 2019-12-16
US20190345165A1 (en) 2019-11-14
MX2019007339A (es) 2019-09-06
EP3562809B1 (fr) 2021-06-09

Similar Documents

Publication Publication Date Title
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3429596A4 (fr) Composés di-nucléotides cycliques et leurs procédés d'utilisation
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA46546A (fr) Composés thérapeutiques et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation